Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Gives Innovation, Harmonization Added Attention In Final Priorities Report

This article was originally published in The Gray Sheet

Executive Summary

The agency made subtle but potentially notable changes from a draft in its final five-year strategic priorities document, released Sept. 30.

You may also be interested in...



FDA Budget Issues Creep Into Strategic Priorities

“Given the limited availability of investment capital for medical product development, early clarification of regulatory requirements is critical,” FDA says.

Cosmetic And Personal Care Trademark Review 7 December, 2021

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Plenity: A Device For Weight Loss that Looks Like A Drug, And Is Sold Like A Consumer Product

Medtech Insight spoke to the chief executive and chief operating officers of Plenity’s manufacturer, Gelesis, to learn more about its weight loss device.

Topics

UsernamePublicRestriction

Register

MT033388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel